Rejection of allogeneic and syngeneic but not MHC class I-deficient tumor grafts by MHC class I-deficient mice.

Freland S, Chambers BJ, Andersson M, Van Kaer L, Ljunggren HG
J Immunol. 1998 160 (2): 572-9

PMID: 9551890

The ability of TAP1-/-, beta2m-/-, and TAP1/beta2m-/- mice to mount rejection responses against allogeneic, syngeneic, and MHC class I-deficient tumor grafts was examined. The results demonstrate a potent ability of TAP1-/- and beta2m-/- as well as TAP1/beta2m-/- mice to reject allogeneic tumors. In contrast to published data, rejection of syngeneic MHC class I-expressing tumors was also observed. This response was specific for the MHC class I-deficient mice, since wild-type mice did not reject syngeneic MHC class I-positive tumors under identical experimental conditions. The rejection response of syngeneic tumors required preimmunization of the mice and was MHC class I specific at the level of priming as well as at the level of the tumor target. Finally, MHC class I-deficient tumor grafts were accepted in MHC class I-deficient mice while similar grafts were rejected in wild-type mice. In summary, while MHC class I-deficient mice have retained a capacity to reject allogeneic tumors. they have gained an ability to reject syngeneic MHC class I-positive tumors and lost the ability to reject MHC class I-negative tumors. The present results are discussed in relation to the role of MHC class I molecules in selecting functional CD8+ T and NK cell repertoires, and the development of cell-mediated immunity.

MeSH Terms (17)

Animals ATP-Binding Cassette Transporters ATP Binding Cassette Transporter, Subfamily B, Member 2 beta 2-Microglobulin Graft Rejection Histocompatibility Antigens Class I Lymphoma, T-Cell Mast-Cell Sarcoma Mice Mice, Inbred C57BL Mice, Knockout Neoplasm Transplantation Sarcoma, Experimental Species Specificity Transplantation, Homologous Transplantation, Isogeneic Tumor Cells, Cultured

Connections (1)

This publication is referenced by other Labnodes entities: